Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs)

Wallace, Daniel J.;Houssiau, Frédéric;Hobbs, Kathryn;Strand, Vibeke;Barry, Anna;et.al.
(2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals — Location: San Francisco (Ca) (24.October.2008)

Files

No attached file found for this publication.

Details

Authors
  • Wallace, Daniel J.
    Author
  • Houssiau, FrédéricUCLouvain
    Author
  • Hobbs, Kathryn
    Author
  • Strand, Vibeke
    Author
  • Barry, Anna
    Author
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Wallace, D. J., Houssiau, F., Hobbs, K., Strand, V., Tak, P.-P., Wegener, W. A., Kelley, L., & Barry, A. (2008). Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs). Arthritis & Rheumatism, 58(9), S571-S572. https://doi.org/10.1002/art.23808 (Original work published 2008)